Menu Back to 12

Track 12: Value and Access

DIA 2017: Driving Insights to Action

The healthcare landscape is evolving into one assessed on value, and there is a need to understand the impact of this movement on all stakeholders – providers, payers, biopharma, and ultimately patients. The Value and Access track will bring together global regulators, industry leaders, patients, and payers who will facilitate discussions and address questions such as:

  • What information and evidence is being used to define value?
  • Who is making or influencing access decisions?
  • How can real-world data be leveraged to drive access to medicines?
  • What are the regulatory and legal considerations surrounding value-based contracting conversations with payers?

Sessions in Value and Access

Sunday, June 23 | Short Courses

  • The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment
  • Machine Learning in Pharmacovigilance
  • Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies
  • The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment

View All Short Courses

Included Topic Areas in Value and Access

DIA 2018’s Program and full list of sessions will be available in January. Meanwhile, see what topics and priorities we are designing content for.

  • Biosimilars, interchangeables, and non-interchangeable: what are the evidence needs? How will reimbursement impact access?
  • Technology and data solutions to assess value and drive reimbursement (e.g., mHealth topics, and others)
  • Developing and partnering on evidence needs for value assessment, including methods focusing on patient-centered care
  • Evolving payment systems and payers needs for radical personalized medicines with focus on rare diseases, genetic approaches (e.g., CRISPR, gene editing) and impact on reimbursement
  • Value-based contracting: lessons from the field of value-based contracts, indication-based pricing, and bundled payments
  • Comparative effectiveness research and current application in decision-making
  • Innovative models and approaches describing the future of value-based care
  • Early HTA scientific advice: optimizing your clinical development program to support reimbursement and patient access
  • Approaches and methods for using Real World Evidence to increase market access
  • Best practices and approaches for medical monitoring in non-interventional studies (NIS) to ensure healthcare value

Who is This Track Designed For?

Professionals involved in: Health economics outcomes, statistics, data modeling, clinical research, postmarketing, regulatory affairs, and health economy.

View Other Tracks

Registration Rates

Back to DIA 2018

Back to